Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government-implemented demonstration program

BMC Public Health

Vivien Davis Tsu¹  Nguyen Tran Hien⁶  Dang Thi Thanh Huyen⁶  Amynah Janmohamed⁴  Le Thi Nga²  Nguyen Quy Nghi³  D Scott LaMontagne⁵ 

[1] Reproductive Health Global Program, PATH, PO Box 900922, Seattle, WA 98109, USA;HealthBridge, Suite 202&203, E4 Building, Trung Tu Diplomatic Compound, No.6 Dang Van Ngu, DongDa, Hanoi, Vietnam;World Bank, 8th Floor, 63 Ly Thai To, Hanoi, Vietnam;Faculty of Land and Food Systems, University of British Columbia, 2357 Main Mall, Vancouver, BC V6T1Z4, Canada;Vaccine Access & Delivery Department, PATH, PO Box 900922, Seattle, WA 98109, USA;National Expanded Program on Immunization, National Institute of Hygiene and Epidemiology, 1 Yersin St, Hai Ba Trung District, Hanoi, Vietnam

关键词: Vietnam;    Vaccine delivery;    School-based;    Health system;    Feasibility;    HPV vaccine;   

Others  :  1129852
DOI  :  10.1186/1471-2458-14-556

 received in 2013-06-13, accepted in 2014-05-30,  发布年份 2014

【 摘 要 】

Background

Introduction of human papillomavirus (HPV) vaccine in national programs has proceeded apace since 2006, mostly in high-income countries. Recently concluded pilots of HPV vaccination in low-income countries have provided important lessons learned for these settings; however, rigorous evaluations of the feasibility of these delivery strategies that effectively reach young adolescents have been few. This paper presents results from a qualitative evaluation of a demonstration program which implemented school-based and health center–based HPV vaccinations to all girls in grade 6, or 11 years of age, for two years in four districts of Vietnam.

Methods

Using semi-structured interviews of 131 health and education staff from local, district, province, and national levels and 26 focus-group discussions with local project implementers (n = 153), we conducted a qualitative two-year evaluation to measure the impact of HPV vaccinations on the health and education systems.

Results

HPV vaccine delivery at schools or health centers was made feasible by: a. close collaboration between the health and education sectors, b. detailed planning for implementation, c. clearly defined roles and responsibilities for project implementers, d. effective management and supervision of vaccinations during delivery, and e. engagement with community organizations for support. Both the health and education systems were temporarily challenged with the extra workload, but the disruptions were short-lived (a few days for each of three doses) and perceived as worth the longer-term benefit of cervical cancer prevention.

Conclusion

The learning from Vietnam has identified critical elements for successful vaccine delivery that can provide a model for other countries to consider during their planning of national rollout of HPV vaccine.

【 授权许可】

   
2014 LaMontagne et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]The FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
• [2]Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
• [3]LaMontagne DS: HPV vaccination in low-resource countries: current evidence and global update. Public Health workshop. 28th International Papillomavirus Conference, San Juan, Puerto Rico, December 1, 2012.
• [4]Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM: Human papillomavirus vaccine introduction--the first five years. Vaccine 2012, 30(Suppl 5):F139-F148.
• [5]Koulova A, Tsui J, Irwin K, Van DP, Biellik R, Aguado MT: Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008, 26(51):6529-6541.
• [6]Munoz N: Progress in HPV vaccine introduction in Latin America. HPV Today 2012, 27:10-11.
• [7]Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F: Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012, 90(8):623-628.
• [8]Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H: HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011, 29(19):3610-3616.
• [9]Chadenier GM, Colzani E, Faccini M, Borriello CR, Bonazzi C: Assessment of the first HPV vaccination campaign in two northern Italian health districts. Vaccine 2011, 29(26):4405-4408.
• [10]Kramer MR, Dunlop AL: Inter-State variation in human papillomavirus vaccine coverage among adolescent girls in the 50 US states, 2007. Matern Child Health J 2012, 16(Suppl 1):S102-S110.
• [11]Brotherton JM, Leask J, Jackson C, McCaffery K, Trevena LJ: National survey of general practitioners’ experience of delivering the National Human Papillomavirus Vaccination Program. Sex Health 2010, 7(3):291-298.
• [12]Widgren K, Simonsen J, Valentiner-Branth P, Molbak K: Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Vaccine 2011, 29(52):9663-9667.
• [13]Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, Simard JF: Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206(6):860-866.
• [14]Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM: Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206(11):1645-1651.
• [15]Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44.
• [16]Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, McCann R: Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008, 336(7652):1056-1058.
• [17]Robbins SC, Bernard D, McCaffery K, Skinner SR: ‘It’s a logistical nightmare!’ Recommendations for optimising human papillomavirus school-based vaccination experience. Sex Health 2010, 7(3):271-278.
• [18]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [19]Penny M, Bartolini R, Mosqueira NR, LaMontagne DS, Mendoza MA, Ramos I, Winkler JL, Villafana J, Janmohamed A, Jumaan AO: Strategies to vaccinate against cancer of the cervix: Feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011, 29:5022-5030.
• [20]Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J: Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 2012, 12:370. BioMed Central Full Text
• [21]Bingham A, Drake JK, LaMontagne DS: Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009, 163(5):455-461.
• [22]Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, Gandhi S: Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009, 27(44):6203-6209.
• [23]Jacob M, Mawar N, Menezes L, Kaipilyawar S, Gandhi S, Khan I, Patki M, Bingham A, LaMontagne DS, Bagul R, Katendra T, Karandikar N, Madge V, Chaudhry K, Paranjape R, Nayyar A: Assessing the environment for introduction of human papillomavirus vaccine in India. Open Vacc J 2010, 3:96-107.
• [24]Nghi NQ, LaMontagne DS, Bingham A, Rafiq M, Mai LTP, Lien NT, Khanh NC, Hong DT, Huyen DT, Tho NT, Hien NT: Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health 2010, 7(3):262-270.
• [25]LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO: Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011, 89(11):821-830B.
• [26]Cover JK, Nghi NQ, LaMontagne DS, Huyen DT, Hien NT, Nga LT: Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health 2012, 12:629. BioMed Central Full Text
• [27]Levin CE, Minh HV, Odaga J, Rout SS, Diep NTN, Menezes L, Araujo MA, LaMontagne DS: Incremental costs of strategies to deliver human papillomavirus vaccine to young adolescent girls in Peru, Uganda, and Viet Nam. Bull World Health Organ 2013. in press
• [28]MacQueen KM, McLellan-Lemal E, Barthalow K, Milstein B: Team-based codebook development: structure, process, and agreement. In Handbook for team-based qualitative research. Edited by Guest G, MacQueen KM. Lanham: Altamira; 2008:119-136.
• [29]Frankel RM: Standards of qualitative research. In Doing qualitative research. Edited by Crabtree BF, Miller WL. Newbury Park, Calif: Sage Publications; 1992:333-346.
• [30]Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BJ: Initial lessons learned in HPV vaccination. Gynecol Oncol 2008, 109(2 Suppl):S4-S11.
• [31]Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F: HPV vaccine use in the developing world. Vaccine 2006, 24:132-139.
• [32]Bharadwaj M, Hussain S, Nasare V, Das BC: HPV & HPV vaccination: issues in developing countries. Indian J Med Res 2009, 130(3):327-333.
• [33]Bello FA, Enabor OO, Adewole IF: Human papillomavirus vaccination for control of cervical cancer: a challenge for developing countries. Afr J Reprod Health 2011, 15(1):25-30.
• [34]Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, Pitcher H, Scully M, Watson M, Webby R: Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008, 32(4):457-461.
• [35]Binagwaho A, Wagner CM, Nutt CT: HPV vaccine in Rwanda: different disease, same double standard. Lancet 2011, 378(9807):1916.
• [36]Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R: Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis 2012, 206(5):678-686.
• [37]Remes P, Selestine V, Changalucha J, Ross DA, Wight D, de Sanjosé S, Kapiga S, Hayes RJ, Watson-Jones D: A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 2012, 30(36):5363-5367.